STEREOTACTIC RADIOTHERAPY FOR RECURRENT GLIOBLASTOMA (GBM)

被引：0
|
作者：
Anselmo, P. [1 ]
Maranzano, E. [1 ]
Casale, M. [1 ]
Trippa, F. [1 ]
Italiani, M. [1 ]
Rossi, R. [1 ]
Di Palma, A. [1 ]
Chirico, L. [1 ]
Basagni, M. L. [1 ]
Giorgi, C.
机构：
[1] Radiation Oncol Ctr, Terni, Italy
来源：
RADIOTHERAPY AND ONCOLOGY | 2010年 / 96卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
767
引用
收藏
页码：S272 / S272
页数：1
相关论文
共 50 条
  • [21] Stereotactic radiosurgery and bevacizumab for recurrent glioblastoma
    Sheehan, Jason P.
    Mantziaris, Georgios
    Bunevicius, Adomas
    JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (01) : 229 - 230
  • [22] Hypofractionated stereotactic reirradiation for recurrent glioblastoma
    Yazici, Gozde
    Cengiz, Mustafa
    Ozyigit, Gokhan
    Eren, Gulnihan
    Yildiz, Ferah
    Akyol, Fadil
    Gurkaynak, Murat
    Zorlu, Faruk
    JOURNAL OF NEURO-ONCOLOGY, 2014, 120 (01) : 117 - 123
  • [23] MOLECULAR PREDICTORS OF RESPONSE TO SELINEXOR IN RECURRENT GLIOBLASTOMA (GBM)
    Walker, Christopher
    Shen, Yao
    Mau-Soerensen, Morten
    Wen, Patrick
    van den Bent, Martin
    Plotkin, Scott
    Walenkamp, Annemiek
    Green, Adam
    Califano, Andrea
    Chang, Hua
    Tamir, Sharon
    Henegar, Leah
    Shacham, Sharon
    Alvarez, Mariano
    Landesman, Yosef
    Lassman, Andrew
    NEURO-ONCOLOGY, 2020, 22 : 7 - 7
  • [24] Bevacizumab and daily temozolomide for recurrent glioblastoma multiforme (GBM)
    Maron, R.
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Quinn, J. A.
    Rich, J. N.
    Gururangan, S.
    Wagner, S. A.
    Salacz, M. E.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [25] Molecular predictors of response to selinexor in recurrent glioblastoma (GBM).
    Walker, Christopher James
    Shen, Yao
    Mau-Sorensen, Morten
    Wen, Patrick Y.
    Van den Bent, Martin J.
    Plotkin, Scott Randall
    Walenkamp, Anna Maria Elisabeth
    Green, Adam
    Califano, Andrea
    Chang, Hua
    Henegar, Leah
    Shacham, Sharon
    Alvarez, Mariano J.
    Landesman, Yosef
    Lassman, Andrew B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [26] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)
    Beal, K.
    Omuro, A.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Yamada, Y.
    Abrey, L. E.
    Gutin, P. H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S129 - S129
  • [28] Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme (GBM)
    Raval, Sumul N.
    Rule, Amy
    Hwang, Shirley S.
    NEURO-ONCOLOGY, 2006, 8 (04) : 482 - 482
  • [29] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Assessing the Outcomes of Personalized Ultra-Fractionated Stereotactic Adaptive Radiotherapy in Reirradiation for Recurrent Glioblastoma
    Schmitt, L. Giuliani
    Dohopolski, M.
    Patel, T.
    Patel, A. R.
    Barnett, S.
    Youssef, M.
    Shaikh, N.
    Cai, X.
    Wardak, Z.
    Timmerman, R. D.
    Dan, T.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E231 - E231
12345